Compare Citius Pharmaceuticals Inc (CTXR) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Extra Space Storage, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Extra Space Storage, Inc. trades at $134.22 (market cap $28.12B). The key difference: Extra Space Storage, Inc. is far larger — about 2064.6× Citius Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Extra Space Storage, Inc. for 108 Days on average.
| CTXR | EXR | |
|---|---|---|
Market Cap | $13.62M | $28.12B |
Volume | 132,438 | 2,595,579 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $152.85 |
52-Week Low | $0.48 | $126.67 |
Typical Hold Time | 16 Days | 108 Days |
Enterprise Value | $3.79M | $41.84B |
Dividend Yield | — | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
EXR trades at $133.3, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin improved to 27.79%. Analyst consensus is split evenly between Buy and Hold, with a $158.33 price target suggesting upside. Recent news highlights leadership transition and institutional buying interest.
Outlook is mixed: solid fundamentals and analyst targets support growth, but technical weakness and high valuation ratios pose risks. Investors should weigh steady cash flow and dividend yield against debt levels and market sentiment shifts ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
